Full Press Release Details
Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 4, 2024 (GLOBE NEWSWIRE) - Serina Therapeutics ("Serina") (NYSE American: SER), a clinical-stage biotechnology
company developing its proprietary POZ Platform drug delivery technology, today announced that Steve Ledger, Interim Chief
Executive Officer of Serina, will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 11, 2024, at 12:00
live webcast of the presentation can be accessed from the Investor section of Serina's website, where an archived replay
of the event will also be available for a limited time.
is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases
and other indications. Serina's POZ Platform provides the potential to improve the integrated efficacy and safety profile
of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Serina is headquartered
in Huntsville, Alabama on the campus of the HudsonAlpha Institute of Biotechnology. For more information, please visit https://serinatherapeutics.com.
inquiries, please contact: